Literature DB >> 12225902

The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta.

Pablo Villoslada1, Lisa F Barcellos, Jordi Rio, Ann B Begovich, Mar Tintore, Jaume Sastre-Garriga, Sergio E Baranzini, Pilar Casquero, Stephen L Hauser, Xavier Montalban, Jorge R Oksenberg.   

Abstract

The HLA-DR2 haplotype (DRB1*1501, DQB1*0602) on chromosome 6p21 has consistently demonstrated both association and linkage with multiple sclerosis (MS) in case-control and family studies, particularly in Caucasians of Northern European descent. However, the role of a gene within this region in determining clinical features or response to immunotherapy remains largely unknown. A new familial MS data set from the Mediterranean Spanish Basin was collected according to rigorous ascertainment criteria. We confirm, primarily in the cohort originating from Continental Spain, that similar to other high-risk groups, there was a significant association with HLA-DR2. No other DR or DQ alleles were found to be associated with disease susceptibility nor were alleles at the class I A and B loci. Overall, the effect of HLA appears to be less substantial than that observed in a reference US population with a higher disease incidence. No effect of the HLA-DR2 haplotype on age of onset, initial clinical symptoms and disease course was observed. Similarly, no difference in the distribution of responders and nonresponders to interferon-beta (IFNB) therapy, as defined by primary and secondary end points, was observed when individuals were stratified according to HLA-DR2 status.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225902     DOI: 10.1016/s0165-5728(02)00215-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

Review 1.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

2.  Absence of the tag polymorphism for the risk haplotype HLA-DR2 for multiple sclerosis in Wixárika subjects from Mexico.

Authors:  G V González-Enríquez; B M Torres-Mendoza; J Márquez-Pedroza; M A Macías-Islas; G G Ortiz; J A Cruz-Ramos
Journal:  Immunogenetics       Date:  2018-02-03       Impact factor: 2.846

3.  Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients.

Authors:  Catherine O'Doherty; Alexander Favorov; Shirley Heggarty; Colin Graham; Olga Favorova; Michael Ochs; Stanley Hawkins; Michael Hutchinson; Killian O'Rourke; Koen Vandenbroeck
Journal:  Pharmacogenomics       Date:  2009-07       Impact factor: 2.533

Review 4.  Defining and scoring response to IFN-β in multiple sclerosis.

Authors:  Maria Pia Sormani; Nicola De Stefano
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

Review 5.  Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Authors:  Til Menge; Martin S Weber; Bernhard Hemmer; Bernd C Kieseier; Hans-Christian von Büdingen; Clemens Warnke; Scott S Zamvil; Aaron Boster; Omar Khan; Hans-Peter Hartung; Olaf Stüve
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  Predicting responders to therapies for multiple sclerosis.

Authors:  Jordi Río; Manuel Comabella; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2009-10       Impact factor: 42.937

7.  Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures.

Authors:  D T Okuda; R Srinivasan; J R Oksenberg; D S Goodin; S E Baranzini; A Beheshtian; E Waubant; S S Zamvil; D Leppert; P Qualley; R Lincoln; R Gomez; S Caillier; M George; J Wang; S J Nelson; B A C Cree; S L Hauser; D Pelletier
Journal:  Brain       Date:  2008-11-20       Impact factor: 13.501

Review 8.  Optimising MS disease-modifying therapies: antibodies in perspective.

Authors:  Gavin Giovannoni
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

9.  Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.

Authors:  Carlos López-Gómez; Almudena Pino-Ángeles; Teresa Órpez-Zafra; María Jesús Pinto-Medel; Begoña Oliver-Martos; Jesús Ortega-Pinazo; Carlos Arnáiz; Cristina Guijarro-Castro; Jezabel Varadé; Roberto Álvarez-Lafuente; Elena Urcelay; Francisca Sánchez-Jiménez; Óscar Fernández; Laura Leyva
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

10.  Influence of CCR5-Delta32 genotype in Spanish population with multiple sclerosis.

Authors:  D Otaegui; J Ruíz-Martínez; J Olaskoaga; J I Emparanza; A López de Munain
Journal:  Neurogenetics       Date:  2007-03-10       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.